GSK antibiotic hits phase 3 goals in gonorrhea
17 Apr 2024
Phase 3Clinical ResultQualified Infectious Disease Product
GSK announced positive results from a pivotal phase 3 trial for its potential first-in-class oral antibiotic, gepotidacin, for uncomplicated urogenital gonorrhea in adolescents and adults.
The EAGLE-1 non-inferiority trial compared the efficacy and safety of gepotidacin to the current standard of care, ceftriaxone plus azithromycin, in approximately 600 patients with uncomplicated urogenital gonorrhea. In the trial, gepotidacin demonstrated non-inferiority, with a 92.6% success rate compared to a 91.2% success rate for intramuscular ceftriaxone plus oral azithromycin.
Gepotidacin, the result of a 2013 public-private partnership between GSK and BARDA, is an investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different type II topoisomerase enzymes.
The drug is also in development for uncomplicated urinary tract infections. Last April, GSK
presented positive results from two pivotal phase 3 trials. In the EAGLE-2 trial, gepotidacin demonstrated therapeutic success in 50.6% of patients compared to 47% for nitrofurantoin. In the EAGLE-3 trial, gepotidacin demonstrated therapeutic success in 58.5% of patients compared to 43.6% for nitrofurantoin.
If approved, gepotidacin would be the first in a new class of oral antibiotics for UTIs in over 20 years. When sharing the trial results, GSK had targeted a June 2023 regulatory filing, but has seemingly delayed the submission, later sharing an expected regulatory decision by 2025.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.